Published in Infection on January 01, 1999
Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev (2012) 1.84
Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc Natl Acad Sci U S A (2014) 1.82
In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2004) 1.72
Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother (2003) 1.68
Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One (2012) 1.40
Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ (2003) 1.35
Dynamics of symbiont-mediated antibiotic production reveal efficient long-term protection for beewolf offspring. Front Zool (2013) 0.95
Combination antibiotic therapy for multidrug-resistant Gram-negative bacteria. Ups J Med Sci (2014) 0.90
Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis (2012) 0.85
Can we prevent antimicrobial resistance by using antimicrobials better? Pathogens (2013) 0.82
The antimicrobial effect of blue light: what are behind? Virulence (2017) 0.79
Drug resistance pattern of Pseudomonas aeruginosa strains isolated from cystic fibrosis patients at Isfahan AL Zahra hospital, Iran (2009-2010). Iran J Microbiol (2012) 0.79
Bactericidal antibiotic-phytochemical combinations against methicillin resistant Staphylococcus aureus. Braz J Microbiol (2012) 0.78
Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii. Int J Nanomedicine (2016) 0.77
Ribosomal mutations promote the evolution of antibiotic resistance in a multidrug environment. Elife (2017) 0.75